Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4504 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. CAPTEM as first-line (1L) treatment for advanced grade 3 (G3) gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Introduction: The NETTER-2 trial showed a significant progression-free survival (PFS) benefit with 1L 177Lu-DOTATATE vs. high dose octreotide for patients with advanced G2/G3 GEP-NETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments for patients with G3 GEP-NETs, such as capecitabine + temozolomide (CAPTEM), hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Deshayes E

Authors: Deshayes E, Capdevila J, Gerard L, Navalkissoor S, Srirajaskanthan R,

Keywords: gastroenteropancreatic neuroendocrine tumour, [177lu]lu-dotatate, capecitabine, temozolomide, matching adjusted indirect comparison,

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4494 Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,